Astatine-211 alpha therapy
A rare alpha-emitting halogen that can be attached to antibodies and small molecules like iodine, tested in leukaemia conditioning and brain and ovarian cancer.
Overview
Astatine-211 is an alpha emitter with a 7.2-hour half-life that behaves chemically like iodine, so it can label antibodies and small molecules by radiohalogenation. Its short range and high energy suit micrometastatic and disseminated disease; academic programmes in Gothenburg, Seattle and Japan have tested At-211 antibodies in ovarian cancer and as anti-CD45 conditioning before transplant, and At-211 PSMA and MABG agents are in early trials. Production requires a cyclotron with alpha beams, limiting supply to a few centres.
How it works
At-211 is produced by bombarding bismuth with alpha particles, labelled to a targeting molecule, and delivers high linear-energy-transfer alpha particles over a few cell diameters.
- Alpha emission kills with few decays and overcomes resistance
- Iodine-like chemistry fits existing tracers
- Short half-life limits residual dose
- Very limited production capacity
- Short half-life constrains logistics
- Early clinical stage
Latest papers
topQuery for this technology: (TITLE:"Astatine-211 alpha therapy" OR ABSTRACT:"Astatine-211 alpha therapy") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Astatine-211 alpha therapy, not a curated reading list.
Similar pages
not linked directly; found by shared links- CompanyAriceum Therapeutics
Shares Targeted alpha therapy, Radioligand therapy (beta emitters).
- CompanyARTBIO
Shares Targeted alpha therapy, Radioligand therapy (beta emitters), Prostate cancer.
- IdeaA global medical isotope supply observatory with forecasts and shortage alerts
Shares Targeted alpha therapy, Radioligand therapy (beta emitters).
- CompanyActinium Pharmaceuticals
Shares Targeted alpha therapy, Acute myeloid leukaemia, Prostate cancer.
- CompanyRatio Therapeutics
Shares Targeted alpha therapy, Radioligand therapy (beta emitters).
- CompanyConvergent Therapeutics
Shares Targeted alpha therapy, Prostate cancer.
- TargetGRPR (gastrin-releasing peptide receptor)
Shares Radioligand therapy (beta emitters), Prostate cancer.
- IdeaWhich patients' blood clones will become leukaemia after treatment?
Shares Radioligand therapy (beta emitters), Ovarian cancer, Acute myeloid leukaemia, Prostate cancer.